Introduction
Severe aplastic anemia (AA) is defined as severe pancytope nia with at least two of the following: absolute neutrophil count of less than 500/mm 3 , a platelet count of less than 20 × 10 3 /mm 3 , and reticulocyte count of less than 20 × 10 3 / mm 3 in the presence of bone marrow cellularity of <25%.
1
Underlying pathophysiology in AA is destruction of hema topoietic stem cells (HSCs), etiology of which in many cases remain unidentified. Most of these patients with AA appear to have a component of autoimmune destruction of HSC. [2] [3] [4] Other secondary causes for AA are viral infections, medications, radiation, and toxins. Hepatitisassociated aplastic anemia (HAAA) is one of the rare secondary causes of AA, especially in young adults that typically presents within 3 months of an acute episode of hepatitis. Hepatitis may be severe fulminant, selflimiting, or chronic. 4 In major ity of these cases, the etiology of hepatitis is not identified and is thought to be due to an undetermined virus. 4 Overall prognosis of AA has improved in recent years due to increasing availability of HSC transplant, immunosuppres sive therapy, and supportive care, with survival rates as high as 80%-90% compared with 10%-20% in the 1960s. 5, 6 Prognosis is very similar for different etiologies of AA. Major factor that affects prognosis includes severity of pan cytopenia, initial response to therapy, and patient's age. Untreated, 1year mortality is 70%. Data are lacking to quantify the frequency of these adverse events associated with these supplements. Many of these dietary supplements contain a wide variety of undeclared active components and the nature of adverse event is unpre dictable. Estimated 23,000 emergency visits are attributed to adverse events related to these supplements in the United States. 8 Manifestations vary widely ranging from cardiac manifestations like tachycardia and palpitation to fulminant hepatic failure and AA as in our patient.
Dietary supplements and workout supplements remain regulated through The Food and Drug Administration (FDA) in the United States. If a supplement is found to be unsafe, FDA can have manufacturer remove the product from the market. However, neither safety testing nor FDA approval is required before the marketing of dietary supplement. 
Case presentation
A 21yearold man with no significant past medical history presented to the emergency department with right upper quadrant pain and jaundice for a week. He gave history of dark urine and pale stool of same duration. He also admitted to fatigue, poor appetite, and nausea but denied any fever, chills, diarrhea, or any weight changes. He denied any confu sion, mental status changes, any hematemesis, hematoche zia, or melena. He denied any recent travel outside the United States or highrisk sexual behavior. He denied any history of incarceration or tattoos. He denied history of tobacco use or any recreational drug abuse. He gave history of drinking one to two drinks of alcohol per week and his last drink was 2 weeks prior to presentation. He denied taking any over the counter medication or herbal supplements. However, he admitted to taking "Dust V2," a workout protein supplement for 4 months (ingredients on Table 1 ). He denied family his tory of any liver disease.
On examination, he had diffuse icterus and tender hepato megaly. No clinical stigmata of chronic liver disease was identified. The laboratory evaluation revealed aspartate ami notransferase (AST) of 1224 IU/dL, alanine transaminase (ALT) of 2908 IU/dL, total bilirubin of 9.4 mg/dL, and alka line phosphatase of 86 IU/dL. Complete blood count and prothrombin time (PT) were normal at the time of presenta tion. Initial lab workup for acute hepatitis was unremarkable ( Table 2 ). The baseline serologic workup is shown in Table 3 which ruled out any infectious, autoimmune, or metabolic causes of his liver disease.
Abdominal magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) showed hepatomegaly but no any masses, biliary obstruc tion or portal vein obstruction. He underwent a liver biopsy for further confirmation which revealed lobular inflamma tion with predominant lymphocytes consistent with drug induced hepatitis. Trichrome stain demonstrated mild portal fibrosis with pericellular fibrosis in areas of hepato cyte dropout (Figures 1 and 2 ). Special stains for iron and copper (iron stain and Rhodanine stain) were both negative. A special stain for cytoplasmic inclusions (PAS stain with diastase) was also negative. He was managed conserva tively with supportive therapy and his liver function test (LFT) started to trend down. He felt symptomatically better and was discharged home.
Two months after initial presentation, he was found to have severe pancytopenia on routine blood counts. Labs revealed white blood cell (WBC) count of 1.3 bil/L with neutrophils 0.8 bil/L. His hemoglobin was 8.4 g/dL and platelet count was 19 bil/L. His AST was 546 IU/L, ALT was 1811 IU/L, and total bilirubin was 6.4. Peripheral smear showed severe neutrope nia with thrombocytopenia. Bone marrow biopsy revealed marked hypocellularity (<5%) with stromal damage (Figure 3) . No blasts and no morphologic evidence of malignancy were identified. Flow cytometry was negative for malignancy. Cytogenetic study showed normal karyotype. Bone marrow biopsy was negative for germline mutation and Paroxysmal Nocturnal Hemoglobinuria(PNH) clone. Infectious workup was negative. On extensive literature review, none of the components of the workout supplement were found to cause AA or hepatitis. 9 A diagnosis of HAAA was made as there was a lag time of months before development of anemia and exten sive workup for other etiology for aplastic was negative. His counts failed to improve despite treatment with filgrastim and he was referred for hematopoietic cell transplant (HCT). He underwent 4/6 human leukocyte antigen (HLA)matched related donor HCT with conditioning regimen of thymoglobu lin, fludarabine, and cyclophosphamide. His LFTs remained stable post conditioning regimen. His posttransplant course was complicated by cutaneous graft versus host disease (GVHD) and remains on tacrolimus. His counts have recov ered, LFT normalized and he continues to do well 7 months posttransplant (Table 4) .
Discussion
Hepatitis is fairly common problem in primary care setting and every clinician should be aware of the potential compli cations including AA and ensure proper followup. HAAA as a secondary cause of AA has been reported in 2%-5% of cases in Western literature. 3 Typically it presents in young adults and children, usually male with onset of pancytopenia 1-3 months after episode of acute hepatitis. Our patient had onset within 2 months of initial hepatitis and was continuing to have mild hepatitis at the onset on AA. The etiology of hepatitis is either idiopathic in most cases or due to any of the hepatitis viruses, parvovirus B19, cytomegalovirus, EpsteinBarr virus, or toxin induced as in our case. A possible hepa totropic virus was identified in less than 6% patients with HAAA in two studies. 10, 11 Our case is unique in that describes AA that occurred after toxininduced hepatitis from workout supplement. Most of the cases has been described after viral hepatitis or are idiopathic. We were able to find only one such case report where the hepatitis was caused by toxin. 12 Our case sheds light in the outcome after HCT in toxininduced HAAA. Hepatotoxicity in the form of intrabiliary cholestasis and hepatitis associated with workout supplements has been widely reported but they are not specifically considered mye lotoxic. 12 Time interval of 1-3 months suggests the initial tar get of the immunological response is the liver. This theory is supported by improvement in LFTs to immunosuppressives administered for the bone marrow aplasia. 2, 3 It has been pos tulated that antigens induce CD8 lymphocyte activation and lead to apoptotic destruction of hematopoietic cells. 4 In addi tion, interferongamma is found to be a marrow suppressing cytokine and is secreted by activated T cells. Hepatitis may be of any severity ranging from fulminant hepatitis to asympto matic mild hepatitis. Initial acute hepatitis may resolve or patients may continue to have mild hepatitis as in our patient in up to 40% cases. 13 Typical presentation includes pallor, fatigue, petechial rashes, and infections from pancytopenia. These patients are susceptible for bacterial or invasive fungal infections which are common causes for death. Diagnosis is made by preced ing history of hepatitis and pancytopenia in complete blood count (CBC). Bone marrow biopsy typically shows pro found hypocellularity with morphologically normal residual hematopoietic cells and absence of malignant infiltration and fibrosis. 4 Treatment includes supportive therapy and definitive therapy for AA. 12 Two major treatment options for treating HAAA are bone marrow transplantation (BMT) and immu nosuppressive therapy. Hendren et al. reported resolution of acute hepatitis B-associated AA with antiviral therapy. Patients with severe neutropenia are susceptible to serious infections and may need antibiotics and antifungals. BMT is preferred over immune suppressive therapy if HLAmatched sibling donor is available. In a study, mean survival in 163 patients was 82% after BMT. 4 The survival rate after BMT in HAAA is similar to that for patients without HAAA. Patients who are treated with immunosuppressive therapy are at increased risk of acute myeloid leukemia (AML) or myelodisplastic syndrome (MDS) in later life and need life long clinical monitoring.
In conclusion, HAAA is relatively rare clinical entity where initial hepatitis leads to subsequent AA due to immu nologic mechanisms. Inciting event for initial hepatitis may be any of the viruses or in rare occasion drug induced as in our case. Most of the cases occur in young adults and prompt diagnosis and treatment is crucial as untreated prognosis is poor. Our patient had HLAmatched sibling and was able to get HCT with good outcome.
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